|
1
|
Karkhanis J, Verna EC, Chang MS, Stravitz
RT, Schilsky M, Lee WM and Brown RS Jr; Acute Liver Failure Study
Group, : Steroid use in acute liver failure. Hepatology.
59:612–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sarin SK and Choudhury A: Acute-on-chronic
liver failure: Terminology, mechanisms and management. Nat Rev
Gastroenterol Hepatol. 13:131–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu Z, Han M, Chen T, Yan W and Ning Q:
Acute liver failure: Mechanisms of immune-mediated liver injury.
Liver Int. 30:782–794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Association for The Study of the
Liver, . Electronic address. simpleeasloffice@easloffice.euClinical
practice guidelines panel. Wendon J Panel members, Cordoba J,
Dhawan A, Larsen FS, Manns M, Samuel D, et al: EASL clinical
practical guidelines on the management of acute (fulminant) liver
failure. J Hepatol. 66:1047–1081. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu X, Liu X, Ling Q, Wei Q, Liu Z, Xu X,
Zhou L, Zhang M, Wu J, Huang J, et al: Artificial liver support
system combined with liver transplantation in the treatment of
patients with acute-on-chronic liver failure. PLoS One.
8:e587382013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krenkel O, Mossanen JC and Tacke F: Immune
mechanisms in acetaminophen-induced acute liver failure.
Hepatobiliary Surg Nutr. 3:331–343. 2014.PubMed/NCBI
|
|
7
|
Jalan R, Gines P, Olson JC, Mookerjee RP,
Moreau R, Garcia-Tsao G, Arroyo V and Kamath PS: Acute-on chronic
liver failure. J Hepatol. 57:1336–1348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donnelly MC, Hayes PC and Simpson KJ: Role
of inflammation and infection in the pathogenesis of human acute
liver failure: Clinical implications for monitoring and therapy.
World J Gastroenterol. 22:5958–5970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Antoniades CG, Berry PA, Wendon JA and
Vergani D: The importance of immune dysfunction in determining
outcome in acute liver failure. J Hepatol. 49:845–861. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Possamai LA, Thursz MR, Wendon JA and
Antoniades CG: Modulation of monocyte/macrophage function: A
therapeutic strategy in the treatment of acute liver failure. J
Hepatol. 61:439–445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chadwick D, Pido-Lopez J, Pires A, Imami
N, Gotch F, Villacian JS, Ravindran S and Paton NI: A pilot study
of the safety and efficacy of thymosin alpha 1 in augmenting immune
reconstitution in HIV-infected patients with low CD4 counts taking
highly active antiretroviral therapy. Clin Exp Immunol.
134:477–481. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiu SJ, Zhou ZG, Shen F, Li AJ, Chen MS,
Ying MG, Chen Z, Zhang YX, Sun HC and Fan J: A multicenter,
randomized, observation-controlled clinical trial to evaluate the
efficacy and safety of thymalfasin adjuvant therapy in patients
with HBV-related HCC after curative resection-first announcement of
the protocol. Expert Opin Biol Ther. 15 Suppl 1:S133–S137. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lao X, Li B, Liu M, Shen C, Yu T, Gao X
and Zheng H: A modified thymosin alpha 1 inhibits the growth of
breast cancer both in vitro and in vivo: Suppressment of cell
proliferation, inducible cell apoptosis and enhancement of targeted
anticancer effects. Apoptosis. 20:1307–1320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Romani L, Bistoni F, Montagnoli C, Gaziano
R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E and
Puccetti P: Thymosin alpha1: An endogenous regulator of
inflammation, immunity, and tolerance. Ann N Y Acad Sci.
1112:326–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu F, Wang HM, Wang T, Zhang YM and Zhu
X: The efficacy of thymosin alpha1 as immunomodulatory treatment
for sepsis: A systematic review of randomized controlled trials.
BMC Infect Dis. 16:4882016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z,
Chen J, Ou-Yang B, Chen M, Li Y, et al: The efficacy of thymosin
alpha 1 for severe sepsis (ETASS): A multicenter, single-blind,
randomized and controlled trial. Crit Care. 17:R82013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li C, Bo L, Liu Q and Jin F: Thymosin
alpha1 based immunomodulatory therapy for sepsis: A systematic
review and meta-analysis. Int J Infect Dis. 33:90–96. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Wang H, Bao S, Tabassam F, Cai W,
Xiang X, Zhao G, Wu H, Gao T, Li H and Xie Q: Amelioration of liver
injury by continuously targeted intervention against TNFRp55 in
rats with acute-on-chronic liver failure. PLoS One. 8:e687572013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng Y, Chen Z, Yu W, Zhou Q, Xu L, Mao
FF, Huang G, Zhang X, Li S, Lahn BT and Xiang AP: Effects of thymic
polypeptides on the thymopoiesis of mouse embryonic stem cells.
Cell Biol Int. 32:1265–1271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romani L, Bistoni F, Gaziano R, Bozza S,
Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A,
Rasi G, et al: Thymosin alpha 1 activates dendritic cells for
antifungal Th1 resistance through toll-like receptor signaling.
Blood. 103:4232–4239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao PL, Lin YC, Sawhney P and Richburg JH:
Transcriptional regulation of FasL expression and participation of
sTNF-alpha in response to sertoli cell injury. J Biol Chem.
282:5420–5431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu YG, Guan XT, Liu ZM, Tian CY and Cui
LC: Immunogenicity in swine of orally administered recombinant
Lactobacillus plantarum expressing classical swine fever virus E2
protein in conjunction with thymosin α-1 as an adjuvant. Appl
Environ Microbiol. 81:3745–3752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garaci E, Pica F, Serafino A, Balestrieri
E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P
and Sinibaldi-Vallebona P: Thymosin α1 and cancer: Action on immune
effector and tumor target cells. Ann N Y Acad Sci. 1269:26–33.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naylor PH and Mutchnick MG: Immunotherapy
for hepatitis B in the direct acting antiviral era: Reevaluating
the thymosin α1 efficacy trials in the light of a combination
therapy approach. J Viral Hepat. Oct 20–2017.(Epub ahead of print).
PubMed/NCBI
|
|
26
|
Camerini R and Garaci E: Historical review
of thymosin α 1 in infectious diseases. Expert Opin Biol Ther. 15
Suppl 1:S117–S127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
King R and Tuthill C: Immune modulation
with thymosin alpha 1 treatment. Vitam Horm. 102:151–178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Romani L, Bistoni F, Perruccio K,
Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G,
Velardi A, et al: Thymosin alpha1 activates dendritic cell
tryptophan catabolism and establishes a regulatory environment for
balance of inflammation and tolerance. Blood. 108:2265–2274. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bozza S, Gaziano R, Bonifazi P, Zelante T,
Pitzurra L, Montagnoli C, Moretti S, Castronari R, Sinibaldi P,
Rasi G, et al: Thymosin alpha1 activates the
TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for
induction of anti-viral responses in vivo. Int Immunol.
19:1261–1270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni
B, Tian Y, Fu XL, Zhang J, Shen ZG, et al: Effect of thymosin
alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells
(Tregs) in vitro. Braz J Med Biol Res. 45:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakama T, Hirono S, Moriuchi A, Hasuike S,
Nagata K, Hori T, Ido A, Hayashi K and Tsubouchi H: Etoposide
prevents apoptosis in mouse liver with
D-galactosamine/lipopolysaccharide-induced fulminant hepatic
failure resulting in reduction of lethality. Hepatology.
33:1441–1450. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chastre A, Belanger M, Beauchesne E,
Nguyen BN, Desjardins P and Butterworth RF: Inflammatory cascades
driven by tumor necrosis factor-alpha play a major role in the
progression of acute liver failure and its neurological
complications. PLoS One. 7:e496702012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang K: Molecular mechanisms of hepatic
apoptosis. Cell Death Dis. 5:e9962014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang P, Shen H, Huang J, Wang H, Zhang B,
Zhou R, Zhong B and Fan X: Intraperitoneal administration of
fetuin-A attenuates D-galactosamine/lipopolysaccharide-induced
liver failure in mouse. Dig Dis Sci. 59:1789–1797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Boomer JS, To K, Chang KC, Takasu O,
Osborne DF, Walton AH, Bricker TL, Jarman SD II, Kreisel D,
Krupnick AS, et al: Immunosuppression in patients who die of sepsis
and multiple organ failure. JAMA. 306:2594–2605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Wang Y, Luo H, Luo Z, Liu L, Xu W,
Zhang T, Yang N, Long X, Zhu N, et al: Ulinastatin reduces urinary
sepsisrelated inflammation by upregulating IL10 and downregulating
TNF-α levels. Mol Med Rep. 8:29–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Volk HD, Reinke P and Döcke WD: Clinical
aspects: From systemic inflammation to ‘immunoparalysis’. Chem
Immunol. 74:162–177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto
Y and Moriwaki H: High levels of serum interleukin-10 and tumor
necrosis factor-alpha are associated with fatality in fulminant
hepatitis. J Infect Dis. 182:1103–1108. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leifeld L, Cheng S, Ramakers J, Dumoulin
FL, Trautwein C, Sauerbruch T and Spengler U: Imbalanced
intrahepatic expression of interleukin 12, interferon gamma, and
interleukin 10 in fulminant hepatitis B. Hepatology. 36:1001–1008.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Orabona C, Puccetti P, Vacca C, Bicciato
S, Luchini A, Fallarino F, Bianchi R, Velardi E, Perruccio K,
Velardi A, et al: Toward the identification of a tolerogenic
signature in IDO-competent dendritic cells. Blood. 107:2846–2854.
2006. View Article : Google Scholar : PubMed/NCBI
|
